Repository logo
 

The microbiota regulates murine inflammatory responses to toxin-induced CNS demyelination but has minimal impact on remyelination.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

McMurran, Christopher E  ORCID logo  https://orcid.org/0000-0002-8710-0930
Guzman de la Fuente, Alerie 
Penalva, Rosana 
Ben Menachem-Zidon, Ofra 
Dombrowski, Yvonne 

Abstract

The microbiota is now recognized as a key influence on the host immune response in the central nervous system (CNS). As such, there has been some progress toward therapies that modulate the microbiota with the aim of limiting immune-mediated demyelination, as occurs in multiple sclerosis. However, remyelination-the regeneration of myelin sheaths-also depends upon an immune response, and the effects that such interventions might have on remyelination have not yet been explored. Here, we show that the inflammatory response during CNS remyelination in mice is modulated by antibiotic or probiotic treatment, as well as in germ-free mice. We also explore the effect of these changes on oligodendrocyte progenitor cell differentiation, which is inhibited by antibiotics but unaffected by our other interventions. These results reveal that high combined doses of oral antibiotics impair oligodendrocyte progenitor cell responses during remyelination and further our understanding of how mammalian regeneration relates to the microbiota.

Description

Keywords

macrophage, microbiota, microglia, oligodendrocyte progenitor cell, remyelination, Animals, Anti-Bacterial Agents, Cell Differentiation, Central Nervous System, Female, Gastrointestinal Microbiome, Humans, Male, Mice, Mice, Inbred C57BL, Multiple Sclerosis, Oligodendroglia, Probiotics, Remyelination, Stem Cells

Journal Title

Proc Natl Acad Sci U S A

Conference Name

Journal ISSN

0027-8424
1091-6490

Volume Title

116

Publisher

Proceedings of the National Academy of Sciences

Rights

All rights reserved
Sponsorship
Medical Research Council (MC_PC_12009)
Medical Research Council (MR/P011705/1)
Medical Research Council (MR/P01836X/1)
Medical Research Council (MC_PC_13030)
This work was supported by grants from UK Multiple Sclerosis Society, The British Trust for the Myelin Project, MedImmune, The Adelson Medical Research Foundation, Wellcome Trust, BBSRC, the Leverhulme Trust and a core support grant from the Wellcome Trust and MRC to the Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute. CEM was supported by grants from the Jean Shanks Foundation and the James Baird Fund, AGF was supported by an ECTRIMS fellowship and OBZ received a BIRAX fellowship.